Brokerages Set AtriCure, Inc. (NASDAQ:ATRC) PT at $51.56

AtriCure, Inc. (NASDAQ:ATRC) has been given a consensus rating of “Buy” by the nine research firms that are presently covering the stock, Marketbeat.com reports. Nine research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have covered the stock in the last year is $49.44.

A number of research firms have recently commented on ATRC. JMP Securities reiterated a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a report on Monday, February 10th. Stifel Nicolaus increased their price target on shares of AtriCure from $36.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. reduced their price objective on shares of AtriCure from $51.00 to $46.00 and set an “overweight” rating for the company in a research report on Thursday, March 27th. Oppenheimer increased their target price on shares of AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, February 13th. Finally, Piper Sandler boosted their price target on shares of AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares in the company, valued at approximately $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.20% of the stock is currently owned by company insiders.

Institutional Trading of AtriCure

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. raised its stake in shares of AtriCure by 1,184.1% during the fourth quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company’s stock worth $49,000 after purchasing an additional 1,492 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in AtriCure during the 4th quarter worth $60,000. Venturi Wealth Management LLC lifted its stake in shares of AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after acquiring an additional 2,100 shares during the period. KBC Group NV boosted its holdings in shares of AtriCure by 65.3% in the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after acquiring an additional 932 shares in the last quarter. Finally, State of Wyoming increased its stake in shares of AtriCure by 21.9% during the fourth quarter. State of Wyoming now owns 2,481 shares of the medical device company’s stock worth $76,000 after acquiring an additional 446 shares during the period. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Stock Performance

NASDAQ:ATRC opened at $32.26 on Tuesday. AtriCure has a 12 month low of $18.94 and a 12 month high of $43.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The firm has a market capitalization of $1.58 billion, a PE ratio of -33.96 and a beta of 1.53. The business’s fifty day moving average price is $37.85 and its 200 day moving average price is $34.06.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.